Bioaffinity Technologies Inc (BIAF)

$1.93

-0.06

(-3.02%)

Market is closed - opens 7 PM, 11 Oct 2024

Performance

  • $1.89
    $1.97
    $1.93
    downward going graph

    2.07%

    Downside

    Day's Volatility :4.06%

    Upside

    2.03%

    downward going graph
  • $1.15
    $3.62
    $1.93
    downward going graph

    40.41%

    Downside

    52 Weeks Volatility :68.23%

    Upside

    46.69%

    downward going graph

Returns

PeriodBioaffinity Technologies IncIndex (Russel 2000)
3 Months
-20.9%
0.0%
6 Months
-17.87%
0.0%
1 Year
32.19%
0.0%
3 Years
-76.75%
-20.3%

Highlights

Market Capitalization
26.8M
Book Value
$0.3
Earnings Per Share (EPS)
-0.91
Wall Street Target Price
6.0
Profit Margin
-119.41%
Operating Margin TTM
-87.08%
Return On Assets TTM
-69.78%
Return On Equity TTM
-151.52%
Revenue TTM
7.3M
Revenue Per Share TTM
0.74
Quarterly Revenue Growth YOY
12047.4%
Gross Profit TTM
0.0
EBITDA
-8.0M
Diluted Eps TTM
-0.91
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.68
EPS Estimate Next Year
-0.6
EPS Estimate Current Quarter
-0.17
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Analyst Forecast

What analysts predicted

Upside of 210.88%

Current $1.93
Target $6.00

Technicals Summary

Sell

Neutral

Buy

Bioaffinity Technologies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bioaffinity Technologies Inc
Bioaffinity Technologies Inc
8.43%
-17.87%
32.19%
-76.75%
-76.75%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-3.46%
-5.93%
6.15%
-22.76%
70.98%
Agilent Technologies Inc.
Agilent Technologies Inc.
2.91%
-0.14%
25.9%
-3.48%
89.56%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.99%
3.35%
20.53%
2.61%
109.35%
Danaher Corp.
Danaher Corp.
-2.03%
9.2%
23.11%
-10.81%
92.08%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-2.97%
-3.26%
12.56%
-4.17%
57.73%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bioaffinity Technologies Inc
Bioaffinity Technologies Inc
NA
NA
NA
-0.68
-1.52
-0.7
NA
0.3
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
47.05
47.05
5.0
10.57
0.63
0.23
NA
19.16
Agilent Technologies Inc.
Agilent Technologies Inc.
29.68
29.68
3.08
5.24
0.25
0.08
0.01
20.53
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
36.9
36.9
2.21
21.73
0.14
0.05
0.0
124.17
Danaher Corp.
Danaher Corp.
48.98
48.98
2.63
7.59
0.08
0.04
0.0
68.92
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.86
29.86
1.12
11.2
0.23
0.05
NA
36.83
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bioaffinity Technologies Inc
Bioaffinity Technologies Inc
NA
$26.8M
-76.75%
NA
-119.41%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$39.0B
70.98%
47.05
22.34%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$41.0B
89.56%
29.68
21.75%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$226.8B
109.35%
36.9
14.69%
Danaher Corp.
Danaher Corp.
Buy
$192.4B
92.08%
48.98
17.83%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$42.0B
57.73%
29.86
9.39%

Insights on Bioaffinity Technologies Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.40M → 2.39M (in $), with an average decrease of 0.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -1.96M → -2.11M (in $), with an average decrease of 7.6% per quarter

Institutional Holdings

  • Vanguard Group Inc

    1.27%
  • Geode Capital Management, LLC

    0.52%
  • CapTrust Financial Advisors

    0.21%
  • Renaissance Technologies Corp

    0.17%
  • Ground Swell Capital, LLC

    0.17%
  • State Street Corp

    0.13%

Company Information

addressing a critical need to find cancer early and treat cancer specifically bioaffinity technologies, inc. develops tests and therapies to detect and treat cancer at the cellular level. our first product, cypath® flow cytometry for lung cancer (cypath® lung), has been licensed by precision pathology services for continued development and commercial sale as a laboratory developed test. cypath® lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures and lower patient anxiety and medical costs.

Organization
Bioaffinity Technologies Inc
Employees
0
CEO
Mr. Steven Girgenti
Industry
Miscellaneous

FAQs